« Return to News | CROs/Service Providers | R&D Trends

AstraZeneca, BioFocus, Argenta collaborate on respiratory and inflammatory diseases

Thursday, March 15, 2012 06:02 AM

Galapagos’ service companies, BioFocus and Argenta, have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets in respiratory and inflammatory diseases.

Each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta, and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta.

 “We continue to be impressed by the strength of the BioFocus and Argenta technology platforms and the evident depth of experience of the scientists that will be engaged on our projects addressing respiratory and inflammatory conditions,” said Dr. John Steele, vice president of R&I Innovative Medicines Science Unit, AstraZeneca.

“Both BioFocus and Argenta have worked extensively with AstraZeneca over the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on,” said Dr. Chris Newton, senior vice president, Galapagos.

Financial details of the collaboration were not disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.